These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Molecularly targeted therapies for malignant gliomas: advances and challenges. Penas-Prado M; Gilbert MR Expert Rev Anticancer Ther; 2007 May; 7(5):641-61. PubMed ID: 17492929 [TBL] [Abstract][Full Text] [Related]
4. Novel chemotherapeutics and other therapies for treating high-grade glioma. Kang JH; Adamson C Expert Opin Investig Drugs; 2015; 24(10):1361-79. PubMed ID: 26289791 [TBL] [Abstract][Full Text] [Related]
5. Cell surface receptors in malignant glioma. Li YM; Hall WA Neurosurgery; 2011 Oct; 69(4):980-94; discussion 994. PubMed ID: 21522029 [TBL] [Abstract][Full Text] [Related]
6. Drug delivery strategies for the treatment of malignant gliomas. Allhenn D; Boushehri MA; Lamprecht A Int J Pharm; 2012 Oct; 436(1-2):299-310. PubMed ID: 22721856 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic targeting of EGFR in malignant gliomas. Ye F; Gao Q; Cai MJ Expert Opin Ther Targets; 2010 Mar; 14(3):303-16. PubMed ID: 20148717 [TBL] [Abstract][Full Text] [Related]
10. Role of p16 and p14ARF in radio- and chemosensitivity of malignant gliomas. Simon M; Voss D; Park-Simon TW; Mahlberg R; Köster G Oncol Rep; 2006 Jul; 16(1):127-32. PubMed ID: 16786135 [TBL] [Abstract][Full Text] [Related]
12. Cancer stem cells and malignant gliomas. From pathophysiology to targeted molecular therapy. Florian IS; Tomuleasa C; Soritau O; Timis T; Ioani H; Irimie A; Kacso G J BUON; 2011; 16(1):16-23. PubMed ID: 21674845 [TBL] [Abstract][Full Text] [Related]
13. The challenges and the promise of molecular targeted therapy in malignant gliomas. Wang H; Xu T; Jiang Y; Xu H; Yan Y; Fu D; Chen J Neoplasia; 2015 Mar; 17(3):239-55. PubMed ID: 25810009 [TBL] [Abstract][Full Text] [Related]
14. The potential of combinations of drug-loaded nanoparticle systems and adult stem cells for glioma therapy. Roger M; Clavreul A; Venier-Julienne MC; Passirani C; Montero-Menei C; Menei P Biomaterials; 2011 Mar; 32(8):2106-16. PubMed ID: 21183214 [TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
17. [Chemotherapy for malignant gliomas: an update]. Wakabayashi T; Natsume A; Fujii M Gan To Kagaku Ryoho; 2013 Oct; 40(10):1283-7. PubMed ID: 24105052 [TBL] [Abstract][Full Text] [Related]
18. The Challenge of Developing New Therapies for Childhood Cancers. Balis FM Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032 [TBL] [Abstract][Full Text] [Related]
19. Does chemotherapy benefit the patient with a central nervous system glioma? Rodriguez LA; Levin VA Oncology (Williston Park); 1987 Nov; 1(9):29-36, 40-1. PubMed ID: 3079493 [TBL] [Abstract][Full Text] [Related]
20. Developing new methods for the treatment of malignant brain tumours: local delivery of anti-neoplastic agents using biodegradable polymers. Olivi A; DiMeco F; Bohan E; Brem H Forum (Genova); 2000; 10(2):152-65. PubMed ID: 10875976 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]